之江生物(688317.SH)2025年度归母净亏损3430.38万元

Core Viewpoint - Zhijiang Biotech (688317.SH) reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to pricing pressures from centralized procurement policies and changes in product sales structure [1] Financial Performance - The company achieved total operating revenue of 124.91 million yuan, a decrease of 30.08% compared to the same period last year [1] - The net profit attributable to the parent company was -34.30 million yuan, representing an increase in loss of 93.16 million yuan year-on-year [1] Factors Affecting Performance - Revenue decline was attributed to the implementation of centralized procurement policies leading to lower sales prices, an increase in the value-added tax rate on self-produced reagent products to 13%, and changes in product sales structure [1] - The decrease in financial income and reduced foreign exchange gains also contributed to the operational losses [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, exploring potential opportunities, and optimizing cost reduction and efficiency improvement measures [1] - Cost control measures have shown effectiveness, with a year-on-year reduction in asset impairment losses, leading to a decrease in operational losses compared to the previous year [1]